Lost is one of the best science fiction shows in television history. Known for its epic cast ensemble, fans wonder where the ...

Lock Stock and Harry Potter actor Nick Moran is already back in the saddle after a brief stint on the sidelines following ...

By Paul Grein UPDATE (April 23): Emmy Award-winning producers Jesse Collins and Dionne Harmon, and Emmy-nominated Jeannae Rouzan-Clay of Jesse Collins Entertainment are set to return as executive ...

Over the last couple of years, one of the best pharma stocks to own has been Eli Lilly (NYSE: LLY). But now, an investment in Lilly may not look so enticing as the possibility of more tariffs loom.

Eli Lilly stock has been a big-time winner over the last couple of years, but looming tariffs are worrying some investors. The pharmaceutical sector could be the next industry to face sweeping ...

A new daily weight-loss pill could be just as effective as the popular injectables that help patients lower their blood sugar and lose unwanted weight. "I think we're really at the beginning of a ...

From late 2020 to the summer of 2024, Eli Lilly & Co. (NYSE: LLY) stock was on a tear, up more than 635%. Last year was a transformative year for the Indianapolis-based pharmaceutical giant ...

Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced success Thursday of its Phase 3 clinical trial for a once-daily GLP-1 pill — an oral form of the blockbuster medication used for ...

Results of the Lilly-funded study provide a promising first look. Diabetics given the pill called orforglipron lost 16 pounds, or 7.9% of their body weight, over a 40-week period.

Eli Lilly & Co.’s stock soared 14% Thursday, to put it on track for its biggest one-day gain in about 25 years, after the drugmaker reported positive results from a late-stage trial of a GLP-1 ...

Eli Lilly's oral GLP-1 drug orforglipron showed strong Phase 3 results with 7.9% weight loss and good tolerability, establishing leadership in obesity treatment. Orforglipron offers advantages ...